Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Reale ML, Chiari R, Tiseo M, Vitiello F, et al. Lung Cancer 2020;140:71-79.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Reale ML, Chiari R, Tiseo M, Vitiello F, et al. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer 2020;140:71-79.
PMID: 31884129